April 30, 2024 | Client News, NASDAQ: OKYO
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA […]
April 30, 2024 | Client News, NASDAQ: MIGI
SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the “Company”), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon. The Phase 1 clinical trial, protocol number KM-NVCoV2-001, which received approval from the regulatory agency in […]
April 29, 2024 | Client News
NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients with Parkinson’s disease. The Company expects to initiate a Phase 1 clinical trial in PD in 2H 2024. SANTA ANA, Calif., April 29, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), […]
April 29, 2024 | Client News
NEW YORK, NY / ACCESSWIRE / April 29, 2024 / 1847 Holdings LLC (“1847” or the “Company”) (NYSE American:EFSH), a holding company specializing in identifying over-looked, deep value investment opportunities in middle market businesses, today provided an update on the sale of 1847 Cabinets Inc. As previously announced on April 23, 2024, the Company executed a non-binding Letter […]
April 26, 2024 | Client News
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal […]
April 26, 2024 | Client News
Nashville, TN, April 26, 2024 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) (“American Rebel” or the “Company”), a designer, manufacturer, and marketer of branded safes, personal security and self-defense products and apparel, and American Rebel Beer (www.americanrebelbeer.com), announces the appointment of Thomas Mihalek as CEO of Champion Safe (www.championsafe.com). American Rebel sells safe […]
April 26, 2024 | Client News
Reduced the Liability of the Senior Loan by Converting $3.0 Million to Equity Extended the Maturity of the Remaining Balance to December 2024 AUSTIN, TX, April 26, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Interactive Strength Inc. (Nasdaq: TRNR) (“TRNR” or “the Company”), maker of innovative specialty fitness equipment under the CLMBR and FORME brands, today […]
April 26, 2024 | Client News
In vitro studies with SNK01 have shown a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting immunoregulatory cytokines and identifying and eliminating autoreactive T cells that contribute to neuroinflammation. SNK01 autologous NK cell therapy demonstrated a positive effect on improving cerebral spinal fluid (“CSF”) and plasma levels of Tau, amyloid, […]
April 26, 2024 | Client News, NASDAQ: LGVN
MIAMI, April 25, 2024 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Planet MicroCap Showcase, taking place May 1-2, 2024. Details for the Company’s presentation: Date: Wednesday, May 1, 2024 Time: 4:30 p.m. PT Webcast: Click Here […]